Sugi Predict

Sugi Predict / Compounds / SCHEMBL188545

SCHEMBL188545

SCHEMBL188545

O=C(O)CNc1cccc(F)c1F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ CXCL8 P10145 1/20 0.44
▸ CES2 O00748 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ RAB9A P51151 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PKM P14618 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ PTGS2 P35354 1/20 0.38
▸ PLA2G7 Q13093 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018214 0.85 CXCL8 (0.54) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
Hydrochloric Acid SCHEMBL28780309 0.85 CXCL8 (0.54) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
SCHEMBL5966407 0.84 ALB (0.47) PARP1SMN1; SMN2CXCL8CES2CES1
SCHEMBL28307658 0.83 CXCL8 (0.53) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
SCHEMBL28122217 0.83 CXCL8 (0.53) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
SCHEMBL28847313 0.83 CXCL8 (0.53) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
SCHEMBL3621497 0.83 ALDH1A1 (0.49) CES2CES1ALDH1A1KDM4EL3MBTL1
SCHEMBL28463827 0.82 ALDH1A1 (0.47) SMN1; SMN2CES2BCHECES1ALDH1A1
SCHEMBL10390693 0.82 SMN1; SMN2 (0.60) PARP1SMN1; SMN2CXCL8ALDH1A1RAB9A
SCHEMBL381570 0.82 ALDH1A1 (0.47) PARP1CXCL8ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687443-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE Genepep (FR) 2026-02-11 — — EP disclosed
WO-2024208878-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE GENEPEP (FR) 2024-10-10 — — WO disclosed
US-20230414702-A1 COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER PEPKON SAS (FR) 2023-12-28 — — US disclosed
US-11759496-B2 Compounds and pharmaceutical use thereof in the treatment of cancer Karoyan, Philippe (FR) 2023-09-19 — — US disclosed
EP-3454879-B1 NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER INST NAT SANTE RECH MED (FR) 2021-12-22 — — EP disclosed
US-10851119-B2 Boron-containing diacylhydrazines INTREXON CORPORATION (US) 2020-12-01 — — US disclosed
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES INTREXON CORP (US) 2020-05-21 — — US disclosed
CN-107406373-B Boron-containing diacylhydrazine compounds 英特瑞克斯顿股份有限公司 2020-04-28 — — CN disclosed
EP-3194359-B1 BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS INTREXON CORP (US) 2020-04-08 — — EP disclosed
US-10570158-B2 Boron-containing diacylhydrazine compounds INTREXON CORPORATION (US) 2020-02-25 — — US disclosed
WO-2001027140-A1 CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH CYTOVIA, INC. (US) 2001-04-19 — — WO disclosed
US-6211235-B1 ALZHEIMERS DISEASE ELAN PHARMACEUTICALS, INC. 2001-04-03 — — US disclosed
US-6207710-B1 FOR THERAPY OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2001-03-27 — — US disclosed
EP-1076563-A1 DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF Cytovia, Inc. (US) 2001-02-21 — — EP disclosed
US-6191166-B1 ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2001-02-20 — — US disclosed
US-6153591-A PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS CYTOVIA, INC. (US) 2000-11-28 — — US disclosed
WO-1999047154-A1 DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 1999-09-23 — — WO disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 — — EP disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS — 1998-08-20 — — WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851119-B2 Boron-containing diacylhydrazines CD22, BRDT, BCR PARP1 4869/4885SMN1; SMN2 1417/4885CXCL8 4647/4885
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES CD22, BRDT, BCR PARP1 4869/4885SMN1; SMN2 1417/4885CXCL8 4647/4885
US-10570158-B2 Boron-containing diacylhydrazine compounds BRDT, CD22, BCR PARP1 4875/4885SMN1; SMN2 1645/4885CXCL8 4535/4885
US-11759496-B2 Compounds and pharmaceutical use thereof in the treatment of cancer VIP, RNASE1, ABCB11 PARP1 2784/4885SMN1; SMN2 1842/4885CXCL8 557/4885
US-20230414702-A1 COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER VIP, RNASE1, ABCB11 PARP1 2784/4885SMN1; SMN2 1842/4885CXCL8 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.